Sagt doch alles, oder nicht.
Typisches Beispiel waren deren Statements bzgl. DNDN.
Mein Auszug ist von der CTIC Homepage, falls es Dir noch nicht aufgefallen ist?!
Und hier mal was zum nachlesen:
http://de.wikipedia.org/wiki/Non-Hodgkin-Lymphom
http://en.wikipedia.org/wiki/Pixantrone
Und dies hier steht in der Fusszeile jeder News:
About Pixantrone
Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.
Hauptmerkmal sind lymphoma, deshalb auch der Name "Non-Hodgkin-Lymphom".
Die Non-Hodgkin-Lymphome zählen zu den malignen Lymphomen, das sind bösartige Erkrankungen des lymphatischen Systems.
http://www.morbus-hodgkin.de/infoserv/nhl.htm |
